Physiological Associations and Prognostic Discrimination of an EIT-Derived Flow Index During Noninvasive Ventilation (NIV-EFI)
Physiological Associations and Prognostic Discrimination of an Electrical Impedance Tomography-Derived Flow Index During Noninvasive Ventilation: A Multicenter Prospective Cohort With a Nested Physiological Substudy
This is a multicenter prospective observational cohort study with a nested physiological substudy. It aims to enroll 220 adults with acute hypoxemic respiratory failure (AHRF) initiating mask noninvasive ventilation (NIV). The study will assess the measurement feasibility, physiological associations, and early prognostic discrimination of the electrical impedance tomography (EIT)-derived flow index (EFI) during NIV. The primary objective is to estimate how well pre-landmark T1 EFI discriminates the risk of endotracheal intubation or all-cause death through 48 hours. A nested physiological substudy (n=20) will evaluate the within-patient association between EFI and airway occlusion pressure across fixed pressure support (PS) levels (5, 10, and 15 cmH2O). Clinical management remains independent of study measurements.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This study will enroll adults with AHRF for whom the treating team has decided to initiate mask NIV. The main cohort (n=220) is observational. EIT data will be acquired at baseline (T0), 60-120 min (T1), 20-24 h (T2), and 42-48 h (T3). The primary predictor is the median EFI across valid breaths during T1 (before the 2-h landmark). The primary endpoint is the first occurrence of endotracheal intubation or all-cause death after 2 h and through 48 h among patients eligible at the 2-h landmark.
A nested, non-randomized physiological substudy (n=20) will be conducted after T1. After confirming safety and obtaining separate informed consent, patients will undergo a fixed sequence of brief pressure support steps (PS 5, 10, and 15 cmH2O) with EPAP and FiO2 held at clinical settings. Brief airway occlusions will be performed at each level to measure occlusion pressure (Pocc and P0.1). The substudy aims to estimate the within-patient association between EFI and |Pocc|. The study was approved by the Ethics Committee of Ruijin Hospital (Approval No. 2026846). Written informed consent is obtained from all participants (and separate consent for the substudy).
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Rui Zhang
- 전화번호: +86-18801119381
- 이메일: ccmzhangrui@foxmail.com
연구 장소
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, 중국, 200025
- Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
연락하다:
- Yun Feng
- 전화번호: +86-17321113771
- 이메일: fy11697@rjh.com.cn
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Adults (aged 18 years or older) with acute hypoxemic respiratory failure (AHRF) for whom the treating clinical team has decided to initiate mask noninvasive ventilation (NIV) in the intensive care unit. A subset of stable patients will participate in the nested physiological sub-study.
설명
Inclusion Criteria:
- Age 18 years or older.
- Clinical diagnosis of AHRF and a decision to initiate NIV through an oronasal or full-face mask (PaO2/FiO2 ≤ 300 mmHg or FiO2 ≥ 0.40 to maintain oxygenation target).
- Consent and enrollment completed before NIV begins or within 60 min of initiation.
- Written informed consent from the patient or authorized representative (separate consent for substudy).
Exclusion Criteria:
- Immediate clinical need for endotracheal intubation or clear contraindication to NIV.
- Facial trauma, severe chest-wall skin injury, or incisions preventing safe placement of EIT belt.
- Contraindication in EIT device manual (e.g., incompatible implanted device).
- Pregnancy or lactation.
- Baseline do-not-intubate (DNI) decision or comfort measures only.
- Inability to obtain valid consent.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
Main Cohort
Adults with AHRF initiating mask NIV (n=220). Observational; T1 EFI is evaluated for discriminating 48-hour intubation or death. |
Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team. Continuous EIT monitoring to derive the dimensionless flow index (EFI). |
|
Nested Physiological Substudy
A subset of the main cohort (n=20). Consenting patients undergo brief, sequential pressure support (PS) adjustments (5, 10, 15 cmH2O) and airway occlusions to measure EFI and |Pocc| associations. |
Standard clinical care through oronasal or full-face mask. Settings are directed by the treating team. Continuous EIT monitoring to derive the dimensionless flow index (EFI). Protocol-specified PS steps (5, 10, 15 cmH2O) and device-supported airway occlusions performed in the physiological substudy. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Endotracheal Intubation or All-Cause Death (2h to 48h)
기간: After 2 hours through 48 hours.
|
The first occurrence of endotracheal intubation or all-cause death after 2 hours and through 48 hours from NIV initiation, among patients alive and still receiving NIV at the 2-hour landmark.Unit of Measure: Proportion of participants (or Event count) |
After 2 hours through 48 hours.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Discrimination Performance (AUC) of T1 EFI
기간: Within 72 hours
|
Area under the receiver operating characteristic curve (AUC) of the pre-landmark T1 EFI for predicting the primary composite endpoint.Unit of Measure: AUC (dimensionless, 0-1) |
Within 72 hours
|
|
Within-Patient Association between EFI and |Pocc|
기간: Within 2 to 6 hours after NIV initiation.
|
The within-patient slope of the association between EFI and the absolute magnitude of occlusion pressure (|Pocc|) across fixed pressure support levels in the physiological sub-study. Unit of Measure: cmH2O per unit of EFI |
Within 2 to 6 hours after NIV initiation.
|
|
Intubation or Death by Day 7
기간: Within day 7
|
ncidence of endotracheal intubation or all-cause mortality by day 7.Unit of Measure: Proportion of participants |
Within day 7
|
|
28-Day All-Cause Mortality
기간: within day 28
|
All-cause mortality rate at day 28.Unit of Measure: Proportion of participants |
within day 28
|
공동 작업자 및 조사자
협력자
협력자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- 2026846
- (2026) Lin Lun Shen No. 846 (기타 식별자: Ethics Committee of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
De-identified analysis datasets may be shared on reasonable request for verification, subject to ethics approval.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .